Get to know our clinical trials

Clinical trial with SOT101 in combination with pembrolizumab to evaluate efficacy and safety in patients with selected advanced/resistant solid tumors.

THE AIM OF THE STUDY IS TO INVESTIGATE WHETHER SOT101 IN COMBINATION WITH PEMBROLIZUMAB IS ABLE TO REDUCE TUMOR SIZE. IT IS POSSIBLE THAT THIS COMBINATION TREATMENT DOES NOT PROVIDE ANY ADDITIONAL BENEFIT IN TERMS OF EFFICACY COMPARED TO PEMBROLIZUMAB ALONE.

Status
In recruitment
headquarters
Madrid

Technical Summary

  • PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM, MULTICENTER STUDY OF SOT101 IN COMBINATION WITH PEMBROLIZUMAB TO EVALUATE EFFICACY AND SAFETY IN PATIENTS WITH SELECTED ADVANCED/RESISTANT SOLID TUMORS. IMMUNOTHERAPY
  • Code EudraCT: 2021-005774-25
  • Protocol number: SC104
  • Promoter: SOTIO
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.